Earnings Call Summary | Natural Health Trends(NHTC.US) Q2 2024 Earnings Conference
Earnings Call Summary | Natural Health Trends(NHTC.US) Q2 2024 Earnings Conference
Net income for Q2 2024 was $173,000, compared to a net loss of $219,000 in Q2 2023, marking an improvement in profitability.The following is a summary of the Natural Health Trends Corp. (NHTC) Q2 2024 Earnings Call Transcript:
以下是Natural Health Trends（NHTC）2024年第二季度業績會交流摘要：
Financial Performance:
金融業績：
Q2 2024 net sales stood at $10.5 million, consistent with Q2 2023, demonstrating stability in revenue despite challenging market conditions.
Gross profit margin for Q2 2024 slightly declined to 74.2% from 74.6% the previous year, influenced by higher costs of the Premium Noni Juice product.
Net income for Q2 2024 was $173,000, compared to a net loss of $219,000 in Q2 2023, marking an improvement in profitability.
2024年第二季度淨銷售額爲1050萬美元，與2023年第二季度持平，表現穩健，儘管市場條件不佳。
2024年第二季度毛利率略微下降至74.2％，低於前一年的74.6％，受到高成本Premium Noni Juice產品的影響。
2024年第二季度淨利潤爲173,000美元，而2023年第二季度淨虧損爲219,000美元，標誌着盈利能力的提高。
Business Progress:
業務進展：
Launched targeted programs to enhance customer loyalty and attract new customers.
Introduced a new product category in North America, the Bio Essence wellness panel, which offers health biomarker testing.
Hosted training events and roadshows in multiple countries to strengthen member engagement and showcase new products like 'Collagen Supreme' in Peru.
推出針對性的計劃，提高客戶忠誠度並吸引新客戶。
在北美推出新的產品類別Bio Essence wellness panel，提供健康生物標誌物測試。
在多個國家舉辦培訓活動和路演活動，以加強會員參與和展示在秘魯推出的新產品“Collagen Supreme”。
Opportunities:
機會：
New product introductions, including at-home health testing kits and health-oriented products, align with the growing consumer emphasis on wellness and personalized health solutions.
新產品推出包括家庭健康檢測套件和健康產品，符合消費者對健康和個性化健康解決方案的不斷關注。
Risks:
風險：
The active member base experienced a decrease of 15% year-over-year, which might impact sales performance moving forward.
活躍會員數量同比下降15％，可能影響未來的銷售業績。
More details: Natural Health Trends IR
更多細節: 自然健康趨勢IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。